CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with PD-L1 Checkpoint Inhibitor to Treat Gastric Cancer

CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI

CARsgen Therapeutics and Huadong Medicine Announce Collaboration Agreement For Zevorcabtagene Autoleucel In Mainland China

Results of a Collaborative Research on CAR T Technology between CARsgen and Shanghai Cancer Institute Published on Molecular Therapy

CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting

CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs

CARsgen Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA

CARsgen Presents North America Phase 2 Updates for CT053 BCMA CAR T at the 7th Annual CAR-TCR Summit

CARsgen Releases the First Clinical Batch of CAR T Cells from its RTP GMP Manufacturing Facility in North Carolina

CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline